Abstract:Balazs Antus, 1, 2 Csilla Paska, 1 Imre Barta 1 1 Department of Pathophysiology, National Koranyi Institute of Pulmonology, Budapest H-1121, Hungary; 2 Department of Pulmonology, National Koranyi Institute of Pulmonology, Budapest H-1121, Hungary Correspondence: Balazs Antus Department of Pathophysiology, National Koranyi Institute of Pulmonology, Piheno ut 1, Budapest H-1121, Hungary Tel +36 1 391 3309 Fax + 36 1 200 7060 Email antusb@hotmail.com Purpose: Fractional exhaled nitric oxide (F E NO 50 ) level and peripheral blood eosinophil count may serve as indicators of airway eosinophilia. The aim of this study was to estimate the diagnostic value of these markers for detecting airway eosinophilia in patients with stable chronic obstructive pulmonary disease (COPD) and those experiencing an acute exacerbation (AECOPD). Patients and Methods: F E NO 50 levels, sputum and blood eosinophil counts were assessed in 53 clinically stable ex-smoker COPD patients and 67 ex-smoker COPD patients experiencing a severe exacerbation. In AECOPD, clinical variables were measured at the time of hospital admission and discharge following treatment. Results: In stable COPD, blood eosinophil count but not F E NO 50 level was found to be a good predictor of airway eosinophilia (area under the receiver operating characteristic curve [ROC AUC]: ≥ 0.82). The sensitivity and the specificity of the test ranged between 75% and 98%, the negative predictive value (NPV) was high (> 90%). In AECOPD, F E NO 50 was predictive for airway eosinophilia (ROC AUC: > 0.8) with high NPV (> 88%), but with lower sensitivity and specificity (64– 70%). In contrast, the predictive accuracy of blood eosinophil count for airway eosinophilia in AECOPD was modest (ROC AUC: 0.54– 0.63). The combined use of the two markers provided only limited additional benefit. Correlation analyses supported ROC curve findings. Conclusion: In stable COPD the peripheral blood eosinophil count, while in AECOPD the F E NO 50 level is a good surrogate marker of airway eosinophilia. Keywords: biomarker, exacerbation, predictive, sensitivity, specificity, surrogate

[Assessment of blood eosinophil count in respiratory disease from primary care]

Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD

Measurement of Blood Eosinophils in Asthma and Chronic Obstructive Pulmonary Disease

Clinical factors associated with baseline blood eosinophils among patients with asthma or COPD: NOVELTY study

Blood eosinophil levels as a biomarker in COPD

Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation

Blood eosinophils in COPD and the future risk of pneumonia

Relationship between blood eosinophil count (Eos), clinical characteristics and mortality of patients with COPD

Predictive Value of Exhaled Nitric Oxide and Blood Eosinophil Count in the Assessment of Airway Eosinophilia in COPD

Moderate-High Blood Eosinophilia Is Associated with Increased Hospitalization and Other Asthma Comorbidities

Blood eosinophil variability in patients presenting with acute exacerbations of COPD within the past year and its correlation with treatment plan

Blood Eosinophil Reference Values and Determinants in a Representative Adult Population

Blood eosinophils in COPD: friend or foe?

Small-Airway Function Variables in Spirometry, Fractional Exhaled Nitric Oxide, and Circulating Eosinophils Predicted Airway Hyperresponsiveness in Patients with Mild Asthma.

Improving the diagnosis of eosinophilic asthma

Variability of blood eosinophil count and prognosis of COPD exacerbations

Moderate Accuracy of Peripheral Eosinophil Count for Predicting Eosinophilic Phenotype in Steroid-Naïve Non-Atopic Adult Asthmatics.

Eosinophil count testing in patients with asthma varies by healthcare provider type in the US: a retrospective study

Blood eosinophils predict inhaled fluticasone response in bronchiectasis

Impact of blood eosinophil count on clinical outcomes in hospitalized Syrian patients with COPD exacerbation